Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Madhurantakam, Chaithanya ^a   Duru, Adil D ^a   Sandalova, Tatyana ^a   Webb, John R ^b   Achour, Adnane ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; 3 NITROTYROSINE; 3-NITROTYROSINE; AMINO ACID; DRUG DERIVATIVE; H2 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; TYROSINE; VIRUS PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CRYSTAL STRUCTURE; HYDROGEN BOND; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PROTEIN SECONDARY STRUCTURE; STRUCTURE ANALYSIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; PROTEIN CONFORMATION; PROTEIN STABILITY; X RAY CRYSTALLOGRAPHY;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

AMINO ACIDS; ANIMALS; CRYSTALLOGRAPHY, X-RAY; H-2 ANTIGENS; INFLAMMATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MODELS, MOLECULAR; PEPTIDES; PROTEIN CONFORMATION; PROTEIN STABILITY; RECEPTORS, ANTIGEN, T-CELL; TYROSINE; VIRAL PROTEINS;

EID: 84858213543     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032805     Document Type: Article

References (70)

1. Deribe YL, Pawson T, Dikic I, (2010) Post-translational modifications in signal integration. Nature structural & molecular biology 17: 666-672.
2. Seet BT, Dikic I, Zhou MM, Pawson T, (2006) Reading protein modifications with interaction domains. Nature reviews Molecular cell biology 7: 473-483.
3. Doyle HA, Mamula MJ, (2001) Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 22: 443-449.
4. Uy R, Wold F, (1977) Posttranslational covalent modification of proteins. Science 198: 890-896.
5. Ribet D, Cossart P, (2010) Pathogen-mediated posttranslational modifications: A re-emerging field. Cell 143: 694-702.
6. Utz PJ, Anderson P, (1998) Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 41: 1152-1160.
7. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL, (2006) Post-translational modifications of naturally processed MHC-binding epitopes. Current opinion in immunology 18: 92-97.
8. Petersen J, Purcell AW, Rossjohn J, (2009) Post-translationally modified T cell epitopes: immune recognition and immunotherapy. Journal of molecular medicine 87: 1045-1051.
9. Meadows L, Wang W, den Haan JM, Blokland E, Reinhardus C, et al. (1997) The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6: 273-281.
10. Pierce RA, Field ED, den Haan JM, Caldwell JA, White FM, et al. (1999) Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol 163: 6360-6364.
11. Backlund J, Carlsen S, Hoger T, Holm B, Fugger L, et al. (2002) Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci U S A 99: 9960-9965.
12. Haurum JS, Hoier IB, Arsequell G, Neisig A, Valencia G, et al. (1999) Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 190: 145-150.
13. Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, et al. (1999) Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 163: 3812-3818.
14. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, et al. (2000) Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 192: 1755-1762.
15. Abello N, Kerstjens HA, Postma DS, Bischoff R, (2009) Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins. Journal of proteome research 8: 3222-3238.
16. Aulak KS, Miyagi M, Yan L, West KA, Massillon D, et al. (2001) Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci U S A 98: 12056-12061.
17. Ohmori H, Kanayama N, (2005) Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins. Autoimmun Rev 4: 224-229.
18. Burkhardt H, Kalden JR, Schulze-Koops H, (2001) Chicken and egg in autoimmunity and joint inflammation. Trends Immunol 22: 291-293.
19. Drew B, Leeuwenburgh C, (2002) Aging and the role of reactive nitrogen species. Ann N Y Acad Sci 959: 66-81.
20. Cuzzocrea S, Chatterjee PK, Mazzon E, McDonald MC, Dugo L, et al. (2002) Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol 453: 119-129.
21. Loeser RF, Carlson CS, Del Carlo M, Cole A, (2002) Detection of nitrotyrosine in aging and osteoarthritic cartilage: Correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum 46: 2349-2357.
22. Beckmann JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, et al. (1994) Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 375: 81-88.
23. Shishehbor MH, Hazen SL, (2004) Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr Atheroscler Rep 6: 243-250.
24. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, et al. (2001) Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44: 834-838.
25. Liversidge J, Dick A, Gordon S, (2002) Nitric oxide mediates apoptosis through formation of peroxynitrite and Fas/Fas-ligand interactions in experimental autoimmune uveitis. Am J Pathol 160: 905-916.
26. ter Steege JC, Koster-Kamphuis L, van Straaten EA, Forget PP, Buurman WA, (1998) Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radic Biol Med 25: 953-963.
27. Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, et al. (2001) Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol 281: F948-957.
28. Smith KJ, Kapoor R, Felts PA, (1999) Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9: 69-92.
29. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989.
30. van der Vliet A, Eiserich JP, Shigenaga MK, Cross CE, (1999) Reactive nitrogen species and tyrosine nitration in the respiratory tract: epiphenomena or a pathobiologic mechanism of disease? Am J Respir Crit Care Med 160: 1-9.
31. Pieper GM, Khanna AK, Roza AM, (2002) Prolonging organ allograft survival: potential role of nitric oxide scavengers. BioDrugs 16: 37-45.
32. Giorgio S, Linares E, Capurro Mde L, de Bianchi AG, Augusto O, (1996) Formation of nitrosyl hemoglobin and nitrotyrosine during murine leishmaniasis. Photochem Photobiol 63: 750-754.
33. Nakazawa H, Fukuyama N, Takizawa S, Tsuji C, Yoshitake M, et al. (2000) Nitrotyrosine formation and its role in various pathological conditions. Free radical research 33: 771-784.
34. Birnboim HC, Lemay AM, Lam DK, Goldstein R, Webb JR, (2003) Cutting edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. J Immunol 171: 528-532.
35. Herzog J, Maekawa Y, Cirrito TP, Illian BS, Unanue ER, (2005) Activated antigen-presenting cells select and present chemically modified peptides recognized by unique CD4 T cells. Proceedings of the National Academy of Sciences of the United States of America 102: 7928-7933.
36. Gauba V, Grunewald J, Gorney V, Deaton LM, Kang M, et al. (2011) Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids. Proceedings of the National Academy of Sciences of the United States of America 108: 12821-12826.
37. Hardy LL, Wick DA, Webb JR, (2008) Conversion of tyrosine to the inflammation-associated analog 3′-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells. J Immunol 180: 5956-5962.
38. Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, et al. (2008) Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol 181: 2124-2133.
39. Masopust D, Murali-Krishna K, Ahmed R, (2007) Quantitating the magnitude of the lymphocytic choriomeningitis virus-specific CD8 T-cell response: it is even bigger than we thought. J Virol 81: 2002-2011.
40. Achour A, Harris RA, Persson K, Sundback J, Sentman CL, et al. (1999) Murine class I major histocompatibility complex H-2Dd: expression, refolding and crystallization. Acta crystallographica Section D, Biological crystallography 55: 260-262.
41. Achour A, Michaelsson J, Harris RA, Ljunggren HG, Karre K, et al. (2006) Structural basis of the differential stability and receptor specificity of H-2Db in complex with murine versus human beta2-microglobulin. Journal of molecular biology 356: 382-396.
42. Sandalova T, Michaelsson J, Harris RA, Ljunggren HG, Karre K, et al. (2005) Expression, refolding and crystallization of murine MHC class I H-2Db in complex with human beta2-microglobulin. Acta crystallographica Section F, Structural biology and crystallization communications 61: 1090-1093.
43. Sandalova T, Michaelsson J, Harris RA, Odeberg J, Schneider G, et al. (2005) A structural basis for CD8+ T cell-dependent recognition of non-homologous peptide ligands: implications for molecular mimicry in autoreactivity. The Journal of biological chemistry 280: 27069-27075.
44. Leslie AG, (2006) The integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 62: 48-57.
45. (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763.
46. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
47. Winn MD, Murshudov GN, Papiz MZ, (2003) Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol 374: 300-321.
48. DeLano WL, (2002) The PyMOL Molecular Graphics System. Palo Alto, CA, USA, DeLano Scientific.
49. van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, van Hall T, et al. (2009) Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer research 69: 7784-7792.
50. Achour A, Michaelsson J, Harris RA, Odeberg J, Grufman P, et al. (2002) A structural basis for LCMV immune evasion: subversion of H-2D(b) and H-2K(b) presentation of gp33 revealed by comparative crystal structure.Analyses. Immunity 17: 757-768.
51. Velloso LM, Michaelsson J, Ljunggren HG, Schneider G, Achour A, (2004) Determination of structural principles underlying three different modes of lymphocytic choriomeningitis virus escape from CTL recognition. J Immunol 172: 5504-5511.
52. Marrack P, Rubtsova K, Scott-Browne J, Kappler JW, (2008) T cell receptor specificity for major histocompatibility complex proteins. Current opinion in immunology 20: 203-207.
53. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.
54. Bouvier M, Wiley DC, (1994) Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 265: 398-402.
55. Bouvier M, Guo HC, Smith KJ, Wiley DC, (1998) Crystal structures of HLA-A*0201 complexed with antigenic peptides with either the amino- or carboxyl-terminal group substituted by a methyl group. Proteins 33: 97-106.
56. Collins EJ, Garboczi DN, Wiley DC, (1994) Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature 371: 626-629.
57. Yague J, Marina A, Vazquez J, Lopez De Castro JA, (2001) Major histocompatibility complex class I molecules bind natural peptide ligands lacking the amino-terminal binding residue in vivo. J Biol Chem 276: 43699-43707.
58. Garcia KC, Degano M, Pease LR, Huang M, Peterson PA, et al. (1998) Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 279: 1166-1172.
59. Reiser JB, Darnault C, Guimezanes A, Gregoire C, Mosser T, et al. (2000) Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nat Immunol 1: 291-297.
60. Kopec J, Schneider G, (2011) Comparison of fluorescence and light scattering based methods to assess formation and stability of protein-protein complexes. Journal of structural biology 175: 216-223.
61. Huber R, Carrell RW, (1989) Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 28: 8951-8966.
62. Ventura S, Vega MC, Lacroix E, Angrand I, Spagnolo L, et al. (2002) Conformational strain in the hydrophobic core and its implications for protein folding and design. Nature structural biology 9: 485-493.
63. Montfort WR, Weichsel A, (1997) Thymidylate synthase: structure, inhibition, and strained conformations during catalysis. Pharmacology & therapeutics 76: 29-43.
64. Zachariae U, Grubmuller H, (2006) A highly strained nuclear conformation of the exportin Cse1p revealed by molecular dynamics simulations. Structure 14: 1469-1478.
65. Butler JS, Mitrea DM, Mitrousis G, Cingolani G, Loh SN, (2009) Structural and thermodynamic analysis of a conformationally strained circular permutant of barnase. Biochemistry 48: 3497-3507.
66. Im H, Ryu MJ, Yu MH, (2004) Engineering thermostability in serine protease inhibitors. Protein engineering, design & selection: PEDS 17: 325-331.
67. Tissot AC, Ciatto C, Mittl PR, Grutter MG, Pluckthun A, (2000) Viral escape at the molecular level explained by quantitative T-cell receptor/peptide/MHC interactions and the crystal structure of a peptide/MHC complex. J Mol Biol 302: 873-885.
68. Insaidoo FK, Borbulevych OY, Hossain M, Santhanagopolan SM, Baxter TK, et al. (2011) Loss of T Cell Antigen Recognition Arising from Changes in Peptide and Major Histocompatibility Complex Protein Flexibility: IMPLICATIONS FOR VACCINE DESIGN. The Journal of biological chemistry 286: 40163-40173.
69. Ischiropoulos H, al-Mehdi AB, (1995) Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 364: 279-282.
70. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, et al. (1992) Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 298: 431-437.